Device Sectors
Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
July 27, 2010 3:33 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO , July 27 /- Millennium Laboratories, Inc., a national, research-based medication monitoring company specifically focused on clinicians who treat chronic pain, strongly advocated for an increase in physician reimbursement for point-of-care urine drug screening at the Annual...
Home Medical Equipment Providers Recognize Americans with Disabilities Act 20th Anniversary, Vow to Fight for Greater Access to Care
July 26, 2010 10:37 am | by Bio-Medicine.Org | News | CommentsARLINGTON, Va. , July 26 /PRNewswire-USNewswire/ -- Providers of home medical equipment and services, such as wheelchairs, oxygen therapy, and diabetic supplies, are recognizing the importance of the 20th anniversary of the Americans with Disabilities Act (ADA) today. Home medical...
Yale cell researchers win $2.5M grants
July 26, 2010 10:36 am | by Mass High Tech: The Journal of New England Technology | News | CommentsTwo Yale University scientists working on cell biology have been named as recipients of the 2010 Pioneer Award from the National Institutes of Health, with each recipient receiving a $2.5 million grant and laboratory support for five years.
Abbott to Feature Novel Tests and New Upgrades to Testing Platforms at American Association for Clinical Chemistry Lab Expo
July 26, 2010 8:33 am | by Bio-Medicine.Org | News | CommentsANAHEIM, Calif. , July 26 /- A first-of-its-kind test that detects HIV infection earlier than ever before in the United States ; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow...
Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
July 26, 2010 8:32 am | by Bio-Medicine.Org | News | CommentsSANTA BARBARA, Calif. , July 26 /- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent...
Calibra Gains FDA Clearance to Market Finesse™ Insulin Patch-Pen for Three-Day Use With Novolog®
July 26, 2010 7:35 am | by Bio-Medicine.Org | News | CommentsREDWOOD CITY, Calif. , July 26 /- Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk's Novolog ® rapid acting insulin. Combining the...
Circle Biologics® Introduces Innovation in Medical Devices
July 26, 2010 7:35 am | by Bio-Medicine.Org | News | CommentsMINNEAPOLIS , July 26 /- Circle Biologics®, Inc. has announced a technological break-through in regenerative medicine – its Autologous Platelet Concentrator Platform (APC™). This innovative single device platform is the first of its kind to incorporate both...
Brainlab Offers Real-Time Monitoring for IGRT
July 26, 2010 7:34 am | by Bio-Medicine.Org | News | CommentsWESTCHESTER, Ill. , July 26 /- Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM)...
Boston Scientific Launches Neuroform EZâ„¢ Stent System in U.S. and Europe
July 26, 2010 4:34 am | by Boston Scientific | News | CommentsCompany expands market-leading family of neurovascular stents
Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
July 26, 2010 3:36 am | by Bio-Medicine.Org | News | CommentsEMERYVILLE, Calif. , July 26 /- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma....
Delcath Systems Announces Second Quarter Progress Report Conference Call
July 26, 2010 3:36 am | by Bio-Medicine.Org | News | CommentsNEW YORK , July 26 /- Delcath Systems, Inc. (Nasdaq: DCTH ) announced today that it will host a conference call to discuss its second quarter results and recent corporate developments on Thursday, July 29, 2010 at 4:30pm, ET . Eamonn Hobbs , President and Chief Executive Officer, and...
Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity
July 26, 2010 3:36 am | by Bio-Medicine.Org | News | CommentsTEMPE, Ariz. , July 26 /- Harco Metal Products (Harco), an industry leader in tube fabrication, systems integration, and seamless, cost effective manufacturing, announced today the contract to manufacture MediGLIDERâ„¢ products for ConMediSys. ConMediSys, the developer of safety...
Gamma-Tocotrienol Kills Prostate Cancer Stem Cells
July 26, 2010 12:33 am | by Bio-Medicine.Org | News | CommentsSINGAPORE , July 25 /PRNewswire-Asia/ -- Scientists from Singapore , Australia and Hong Kong have found that gamma-tocotrienol is potent in killing prostate cancer stem cells. This small group of cells is responsible for the initiation of prostate cancer and is resistant to conventional...
2008 U.S. Diabetes Drug Delivery - Patient Perspective
July 26, 2010 12:33 am | by Bio-Medicine.Org | News | CommentsNEW YORK , July 26 /- Reportlinker.com announces that a new market research report is available in its catalogue: 2008 U.S. Diabetes Drug Delivery - Patient Perspective http://www.reportlinker.com/p0236248/2008-US-Diabetes-Drug-Delivery---Pa... This...
San Diego Businesses Receive Health Care Reform Notices From IRS
July 26, 2010 12:32 am | by San Diego Business Journal | News | CommentsOne of the first provisions of the Healthcare Reform Act to go into effect may provide relief for many San Diego employers in the form of a small business tax credit designed to assist with the cost of providing health insurance to employees, according to Notice 2010-44 issued by the...
The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen
July 26, 2010 12:32 am | by EurekAlert | News | Comments(The Translational Genomics Research Institute) The Marilyn B. Gula Mountains of Hope Foundation continues its fight against advanced breast cancer with a $50,000 donation to the Phoenix-based Translational Genomics Research Institute (TGen), for a total contribution over two years of $300,000.
Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children
July 25, 2010 9:33 pm | by EurekAlert | News | Comments(Children's Hospital of Philadelphia) School-aged children who undergo cardiopulmonary bypass during surgery for less complicated congenital heart defects do not appear to suffer any impairments in neurocognitive abilities, such as intelligence, memory, motor skills and behavior....
Diagnostic 'guidelines' a barrier to prompt relief for some back pain
July 24, 2010 4:34 pm | by EurekAlert | News | Comments(Johns Hopkins Medical Institutions) Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.
Education Tactics for Thought Leaders, Physicians, Patients and Payers to Support Successful Oncology Product Launches
July 23, 2010 4:37 pm | by Bio-Medicine.Org | News | CommentsCHAPEL HILL, N.C. , July 23 /- The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that...
BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
July 23, 2010 4:36 pm | by Bio-Medicine.Org | News | CommentsHERNDON, Va. , July 23 /PRNewswire-USNewswire/ -- BHR Pharma, LLC (BHR) announced today that the first patient has been enrolled in its SyNAPSe study ( www.synapse-trial.com ), a global, Phase 3, pivotal trial to evaluate the safety and effectiveness of its intravenous progesterone...
Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer
July 23, 2010 4:36 pm | by Bio-Medicine.Org | News | CommentsGREAT NECK, N.Y. , July 23 /PRNewswire-USNewswire/ -- The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth) to participate in a Phase I clinical trial. Subjects must be newly diagnosed...
Vermillion Announces Relocation of Corporate Offices to Austin, Texas
July 23, 2010 4:35 pm | by Bio-Medicine.Org | News | CommentsFREMONT, Calif. , July 23 /- Vermillion, Inc. (Nasdaq: VRML ), a molecular diagnostics company, today announced that it is relocating its corporate headquarters from Fremont, California to Austin, Texas . Vermillion has executed a two-year lease for a new principal place of business...
Biotech Firm Takes Steps to Form European Subsidiary
July 23, 2010 9:37 am | by San Diego Business Journal | News | CommentsOceanside-headquartered International Stem Cell Corp. announced July 22 that it has made preliminary financial arrangements to create a new European subsidiary, to be called ISCO Europe.
Momenta surges on first drug approval
July 23, 2010 9:36 am | by Mass High Tech: The Journal of New England Technology | News | CommentsMomenta Pharmaceuticals Inc. surged 76 percent in midday trading Friday on the U.S. Food and Drug Administration's approval of its generic version of a blockbuster Sanofi-Aventis drug to treat blood clots.
Hijacked supplies for pathogens
July 23, 2010 5:34 am | by EurekAlert | News | Comments(Max-Planck-Gesellschaft) Legionnaire's disease bacteria tap into the material transport in immune cells.
